Novo Nordisk announced in its 2023 Annual Report that it has increased sales by 31% to DKK 232.3B in 2023, and increased its operating profit by 37% in Danish Kroner. Key developments outlined in the Report include:
- a 51% net profit increase and 49% increase in share price;
- a total of DKK75B investment in expanding global production sites in 2023;
- 40.5M people accessed Novo Nordisk’s diabetes care products;
- a summary of the SELECT trial which showed cardiovascular benefits of semaglutide, including a 20% reduction in major adverse cardiovascular events compared to a placebo; and
- an update on Novo Nordisk’s once-weekly insulin product (Insulin icodec).